MedMira Inc(MMIRF)
USD --+0.00%
Reward33Low
Risk76High
📊75%Data
Revenue down 12% YoY
MMIRF
+0.0 · +0.00%
USD · PINK
MedMira Inc | Healthcare
Earnings Deterioration
Market Cap:9.28M
ℹ️
Reward Rating
33
Low
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
76
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on MMIRF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is MedMira Inc?

, a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally.

MMIRF · Verdict

Limited reward · high risk

MMIRF's standout is volatility; cash flow and profitability weigh on the picture.

Based on 88% data coverage

MMIRF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility65/100

    Above average

Watchouts 4

  • Cash flow6/100

    -1311% free-cash-flow margin

  • Profitability9/100

    -1881% net margin · 0% ROE

  • Balance sheet10/100

    Current ratio 0.10

  • Growth25/100

    Rev -36.8% CAGR · earnings +35.2%

Model-based scoring. For information only — not financial advice.

What is MedMira Inc?

, a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 9.28M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (33)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap9.28M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.1
52 Week Low0.012
Last AnnualJuly
IPO Date12/1/1999
IncorporatedUSA
Shares Outstanding697M
No. of EmployeesN/A
IndustryBiotechnology
ExchangePINK
Beta0.662
CurrencyUSD · Reports in CAD